Neuronetics and Alleviant Health Centers Announce Exclusive Partnership

Partnership Will Bring Non-drug NeuroStar® Advanced Therapy for Mental Health to Thousands More Patients

MALVERN, Pa., July 25, 2022 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, including drug-resistant depression and obsessive-compulsive disorder (OCD), today announced a commercial partnership with Alleviant Health Centers (“Alleviant”), a network of full-service mental health clinics that currently operates five locations in Arkansas and plans to expand its service footprint. Under the partnership agreement, Neuronetics will be the exclusive supplier of new transcranial magnetic stimulation (TMS) equipment to Alleviant and its clinics, with an initial six NeuroStar Advanced Therapy systems delivered in 2022.

“We are delighted to partner with Alleviant to provide more people who need it with access to NeuroStar as a new possibility for non-drug depression treatment,” said Keith J. Sullivan, President and CEO of Neuronetics. “Alleviant’s commitment to offering innovative solutions and their focus on making the world a better place by improving the lives of others makes this an ideal match for us.”

NeuroStar Advanced Therapy is a non-invasive, non-drug treatment that uses transcranial magnetic stimulation to target key areas of the brain that are underactive in people with major depressive disorder (MDD). NeuroStar is the leading TMS treatment for depression in adult patients and has been proven to be safe and effective, with over 4.5 million treatments delivered to over 127,000 patients to-date. Patients treated with NeuroStar achieved a high response rate of 83% and a remission rate of 62% (Sackeim, et al. 2020).

“I care so much about people who are suffering, and I believe it is my responsibility to share proven clinical solutions and knowledge to everyone burdened with conditions we know how to treat,” said Brian Mears, CRNA, Founder, President & CEO of Alleviant Health Centers. “We were using a different TMS device and decided to partner with Neuronetics because the support they provide for our clinics and the tremendous treatment outcomes with NeuroStar TMS will enable us to continue to grow our TMS service line and strengthen the patient-centric care that is so important to healing.”

To learn more about NeuroStar® Advanced Therapy, visit www.neurostar.com. To learn more about Alleviant Health Centers, visit www.alleviant.com.

About Neuronetics
Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is redefining patient and physician expectations with its NeuroStar Advanced Therapy for Mental Health. NeuroStar is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication hasn’t helped. NeuroStar is FDA-cleared for adults with major depressive disorder (MDD), as an adjunct for adults with obsessive-compulsive disorder (OCD), and to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression). NeuroStar Advanced Therapy is the leading transcranial magnetic stimulation (TMS) treatment for MDD in adults with over 4.8 million treatments delivered. NeuroStar is backed by the largest clinical data set of any TMS system for depression, including the world’s largest depression Outcomes Registry. Neuronetics is committed to transforming lives by offering an exceptional treatment that produces extraordinary results. For safety and prescribing information, www.neurostar.com. Neuronetics is committed to transforming lives by offering an exceptional treatment option that produces extraordinary results.

About Alleviant Health Centers
Alleviant Health Centers is dedicated to shifting the focus of mental healthcare in the United States from medication-dependent care to a holistic integrated approach, addressing the whole person. The Company vision is to lead the transformation of mental healthcare by offering innovative treatment models, to create healthcare structures that heal the whole person, and to become a resource of education, inspiration, and empowerment to people suffering from mood disorders and chronic pain.

Investor Contact:
Mike Vallie or Mark Klausner
ICR Westwicke
443-213-0499
[email protected]

Media Contact:
EvolveMKD
646-517-4220
[email protected]

error: Content is protected !!